Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study - Journal of Substance Abuse Treatment
The Role of Mu-Opioids for Reward and Threat Processing in Humans: Bridging the Gap from Preclinical to Clinical Opioid Drug Studies | SpringerLink
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain - ScienceDirect
Understanding opioids in veterinary medicine
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action | PNAS
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
A Novel Kappa Opioid Receptor Agonist May Unlock New Treatment Strategies for Pain | Pain Research Forum
A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
The role of the opioid system in decision making and cognitive control: A review | SpringerLink
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
